SG10201913987UA - PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF - Google Patents
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFInfo
- Publication number
- SG10201913987UA SG10201913987UA SG10201913987UA SG10201913987UA SG10201913987UA SG 10201913987U A SG10201913987U A SG 10201913987UA SG 10201913987U A SG10201913987U A SG 10201913987UA SG 10201913987U A SG10201913987U A SG 10201913987UA SG 10201913987U A SG10201913987U A SG 10201913987UA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazin
- pyrrolo
- imidazo
- trifluoroethyl
- carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562242797P | 2015-10-16 | 2015-10-16 | |
US201562267672P | 2015-12-15 | 2015-12-15 | |
US201662301537P | 2016-02-29 | 2016-02-29 | |
US201662352380P | 2016-06-20 | 2016-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201913987UA true SG10201913987UA (en) | 2020-03-30 |
Family
ID=57209916
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201802990RA SG11201802990RA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913986YA SG10201913986YA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913989QA SG10201913989QA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913997WA SG10201913997WA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913999PA SG10201913999PA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913987UA SG10201913987UA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913990RA SG10201913990RA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913993QA SG10201913993QA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201802990RA SG11201802990RA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913986YA SG10201913986YA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913989QA SG10201913989QA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913997WA SG10201913997WA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913999PA SG10201913999PA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913990RA SG10201913990RA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913993QA SG10201913993QA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
Country Status (14)
Country | Link |
---|---|
US (34) | US20170129902A1 (es) |
EP (2) | EP4219503A1 (es) |
JP (4) | JP6770775B2 (es) |
KR (1) | KR20180081523A (es) |
CN (4) | CN116270645A (es) |
AU (3) | AU2016340167B2 (es) |
BR (2) | BR112018007677A2 (es) |
CA (2) | CA3002220C (es) |
HK (1) | HK1263380A1 (es) |
IL (2) | IL258654A (es) |
MX (2) | MX2018004605A (es) |
RU (1) | RU2018117889A (es) |
SG (8) | SG11201802990RA (es) |
WO (1) | WO2017066775A1 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2836833A1 (de) | 1978-08-23 | 1980-04-10 | Volkswagenwerk Ag | Brennkraftmaschine mit in zwei reihen angeordneten zylindern |
WO2011068881A1 (en) | 2009-12-01 | 2011-06-09 | Abbott Laboratories | Novel tricyclic compounds |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
CN116270645A (zh) * | 2015-10-16 | 2023-06-23 | 艾伯维公司 | 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 |
US11512092B2 (en) * | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
JP2020510016A (ja) | 2017-03-09 | 2020-04-02 | アッヴィ・インコーポレイテッド | クローン病及び潰瘍性大腸炎を処置する方法 |
US11564922B2 (en) | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
WO2019016745A1 (en) * | 2017-07-19 | 2019-01-24 | Dr. Reddy's Laboratories Limited | ALTERNATIVE METHODS FOR THE PREPARATION OF PYRROLIDINE DERIVATIVES |
MX2020010322A (es) | 2018-03-30 | 2022-11-30 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
US11926633B2 (en) | 2018-08-31 | 2024-03-12 | Suzhou Pengxu Pharmatech Co., Ltd | Synthesis methods for upadacitinib and intermediate thereof |
CN110872250B (zh) * | 2018-08-31 | 2023-01-10 | 苏州鹏旭医药科技有限公司 | 两种化合物及其制备方法和在合成乌西替尼中的用途 |
US20220002306A1 (en) * | 2018-09-29 | 2022-01-06 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of upadacitinib and preparation method and use thereof |
CN111217819B (zh) * | 2018-11-27 | 2021-05-14 | 杭州科巢生物科技有限公司 | 乌帕替尼的合成方法 |
EP3891151A1 (en) | 2018-12-05 | 2021-10-13 | LEK Pharmaceuticals d.d. | Crystalline phosphate salt of selective jak1 inhibitor upadacitinib |
CN109369659B (zh) * | 2018-12-06 | 2020-10-27 | 浙江师范大学 | 一种jak抑制剂的合成方法 |
WO2020115213A1 (en) | 2018-12-07 | 2020-06-11 | Lek Pharmaceuticals D.D. | Solvate of a selective jak1 inhibitor |
CN109705011B (zh) * | 2019-01-18 | 2021-02-19 | 浙江师范大学 | 一种乌帕替尼中间体的合成方法及中间体 |
CN112888692A (zh) * | 2019-03-01 | 2021-06-01 | 苏州科睿思制药有限公司 | 一种Upadacitinib的晶型及其制备方法和用途 |
WO2020202183A1 (en) | 2019-03-29 | 2020-10-08 | Mylan Laboratories Limited | The process for the preparation of upadacitinib and its intermediates |
CN111909160A (zh) | 2019-05-09 | 2020-11-10 | 苏州鹏旭医药科技有限公司 | 一种乌帕替尼盐类化合物及其制备方法 |
CN110229160A (zh) * | 2019-06-11 | 2019-09-13 | 南京新酶合医药科技有限公司 | (5-甲苯磺酰基-5H-吡咯并[2,3-b]吡嗪-2-基)氨基甲酸乙酯的制备方法 |
CN110117245B (zh) * | 2019-06-21 | 2021-03-02 | 浙江师范大学 | 一种jak抑制剂中间体的合成方法 |
WO2021005484A1 (en) * | 2019-07-11 | 2021-01-14 | Mankind Pharma Ltd. | Pyrrolidine compounds, its salt and use in the preparation of upadacitinib thereof |
CN110615753A (zh) * | 2019-09-02 | 2019-12-27 | 南京新酶合医药科技有限公司 | 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法 |
JP2022549379A (ja) | 2019-09-30 | 2022-11-24 | アッヴィ・インコーポレイテッド | ウパダシチニブによる脊椎関節炎及び乾癬状態の治療 |
CN111072543B (zh) * | 2019-11-13 | 2021-06-04 | 北京海美桐医药科技有限公司 | 一种(3r,4s)-4-乙基吡咯烷-3-羧酸类化合物的制备方法及其应用 |
US20230139156A1 (en) * | 2019-12-19 | 2023-05-04 | Curia Spain, S.A.U. | Process and intermediates for the preparation of upadacitinib |
WO2021176473A1 (en) * | 2020-03-05 | 2021-09-10 | Mylan Laboratories Limited | A process for the preparation of upadacitinib and its intermediates |
WO2021244323A1 (zh) * | 2020-06-05 | 2021-12-09 | 苏州科睿思制药有限公司 | 一种乌帕替尼的晶型及其制备方法和用途 |
CA3189037A1 (en) * | 2020-07-08 | 2022-01-13 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of upadacitinib, preparation method therefor, and use thereof |
WO2022044037A1 (en) | 2020-08-24 | 2022-03-03 | Mylan Laboratories Limited | An improved process for the preparation of upadacitinib intermediate |
EP4319743A1 (en) * | 2021-04-07 | 2024-02-14 | Abbvie Inc. | Cocrystals of upadacitinib |
CN114380837B (zh) * | 2021-12-27 | 2023-06-30 | 上海邈金医药科技有限公司 | 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用 |
WO2023131978A1 (en) * | 2022-01-06 | 2023-07-13 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of upadacitinib |
WO2023138804A1 (en) | 2022-01-20 | 2023-07-27 | Renata Pharmaceutical (Ireland) Limited | Sustained release pharmaceutical composition of upadacitinib |
EP4215196A1 (en) | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
WO2024075131A1 (en) * | 2022-10-03 | 2024-04-11 | Natco Pharma Limited | Co-crystal of upadacitinib and diacetyl-d-tartaric acid and process for the preparation thereof |
CN117285537B (zh) * | 2023-11-27 | 2024-02-06 | 中节能万润股份有限公司 | 一种乌帕替尼的制备方法 |
CN117285536B (zh) * | 2023-11-27 | 2024-02-20 | 中节能万润股份有限公司 | 一种乌帕替尼中间体的制备方法 |
CN117285535B (zh) * | 2023-11-27 | 2024-02-02 | 中节能万润股份有限公司 | 一种乌帕替尼中间体及成盐中间体的制备方法 |
CN117447481A (zh) * | 2023-12-23 | 2024-01-26 | 潍坊医学院 | 一种乌帕替尼-焦谷氨酸盐的无定形物及其制备方法与应用 |
Family Cites Families (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB716327A (en) | 1951-09-05 | 1954-10-06 | Ici Ltd | New heterocyclic compounds |
US3663559A (en) | 1969-12-03 | 1972-05-16 | Union Carbide Corp | Preparation of oxo-furo-pyridines from furylvinyl isocyanates |
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US4053474A (en) | 1976-04-21 | 1977-10-11 | E. R. Squibb & Sons, Inc. | Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidine |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
DE69033614T2 (de) | 1989-10-20 | 2001-04-19 | Kyowa Hakko Kogyo Kk | Kondensierte Purinderivate |
KR927003044A (ko) | 1990-01-11 | 1992-12-17 | 크리스토퍼 케이. 미라벨리 | Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법 |
US6262241B1 (en) | 1990-08-13 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Compound for detecting and modulating RNA activity and gene expression |
DE69233701T2 (de) | 1991-03-18 | 2008-04-10 | New York University | Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor |
JP3147902B2 (ja) | 1991-06-14 | 2001-03-19 | ファルマシア・アンド・アップジョン・カンパニー | イミダゾ〔1,5−a〕キノキサリン |
US5212310A (en) | 1991-12-19 | 1993-05-18 | Neurogen Corporation | Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands |
US5266698A (en) | 1992-04-30 | 1993-11-30 | Neurogen Corporation | Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands |
US5306819A (en) | 1992-08-27 | 1994-04-26 | Neurogen Corporation | Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands |
PL174494B1 (pl) | 1992-11-13 | 1998-08-31 | Idec Pharma Corp | Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B |
WO1994019351A1 (en) | 1993-02-26 | 1994-09-01 | Schering Corporation | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
US5733905A (en) | 1993-07-29 | 1998-03-31 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
US5736540A (en) | 1993-07-29 | 1998-04-07 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US5547975A (en) | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
RU2158127C2 (ru) | 1994-12-23 | 2000-10-27 | Варнер-Ламберт Компани | Способы ингибирования тирозинкиназы рецептора эпидермального фактора роста, азотсодержащие трициклические соединения, фармацевтическая композиция, предназначенная для введения ингибитора тирозинкиназы рецептора эпидермального фактора роста, например, erb-b2, erb-b3 или erb-b4, и противозачаточная композиция |
US5753648A (en) | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5521173A (en) | 1995-01-17 | 1996-05-28 | American Home Products Corporation | Tricyclic benzazepine vasopressin antagonists |
US5763137A (en) | 1995-08-04 | 1998-06-09 | Agfa-Gevaert, N.V. | Method for making a lithographic printing plate |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
FR2742676B1 (fr) | 1995-12-21 | 1998-02-06 | Oreal | Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie |
US5703244A (en) | 1996-11-21 | 1997-12-30 | Abbott Laboratories | Process for preparation of chiral 3-amino-pyrrolidine and analogous bicyclic compounds |
CN1191242C (zh) | 1997-02-05 | 2005-03-02 | 麦克公司 | 不同结晶型的(-)-6-氯-4-环丙乙炔基-4-三氟甲基-1,4-二氢-2h-3,1-苯并噁嗪-2-酮 |
AU756838B2 (en) | 1998-03-04 | 2003-01-23 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
US6245801B1 (en) | 1998-09-14 | 2001-06-12 | Warner-Lambert Company | Branched alkyl pyrrolidine-3-carboxylic acids |
US6448253B1 (en) | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
DE19853665B4 (de) | 1998-11-20 | 2005-06-30 | Siemens Ag | Fahrzeugkommunikationssystem und Verfahren zum Austausch von Daten in einem Kraftfahrzeug |
CO5271670A1 (es) | 1999-10-29 | 2003-04-30 | Pfizer Prod Inc | Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas |
TWI271406B (en) | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
AU2001285401A1 (en) | 2000-08-07 | 2002-02-18 | Neurogen Corporation | Heterocyclic compounds as ligands of the GABAa receptor |
GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
GB0124299D0 (en) | 2001-10-10 | 2001-11-28 | Astrazeneca Ab | Crystal structure of enzyme and uses thereof |
CA2476822A1 (en) | 2002-02-19 | 2003-08-28 | Pharmacia Italia S.P.A. | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents |
US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
NZ539390A (en) | 2002-10-09 | 2007-05-31 | Scios Inc | Azaindole derivatives as inhibitors of p38 kinase |
EP1590341B1 (en) | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
EP1460088A1 (en) | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
AR044510A1 (es) | 2003-04-14 | 2005-09-14 | Merck & Co Inc | Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina |
US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7592466B2 (en) | 2003-10-09 | 2009-09-22 | Abbott Laboratories | Ureas having antiangiogenic activity |
CA2540868A1 (en) | 2003-10-09 | 2005-04-21 | Abbott Laboratories | Pyrrolidinyl urea derivatives as angiogenesis inhibitors |
US20060074102A1 (en) | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
AR049300A1 (es) | 2004-06-15 | 2006-07-12 | Schering Corp | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos |
WO2006009769A1 (en) | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
ATE455777T1 (de) | 2004-07-23 | 2010-02-15 | Medicines Co Leipzig Gmbh | Substituierte pyridoä3',2':4,5üthienoä3,2- düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü- pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung |
SG156685A1 (en) | 2004-07-27 | 2009-11-26 | Sgx Pharmaceuticals Inc | Fused ring heterocycle kinase modulators |
US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
CN100381175C (zh) | 2004-10-09 | 2008-04-16 | 山西中医学院 | 一种微乳制剂及其制备方法 |
NZ555566A (en) | 2004-11-22 | 2009-12-24 | Vertex Pharma | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
PL1838677T3 (pl) | 2004-12-21 | 2010-02-26 | Arena Pharm Inc | Krystaliczne postacie agonisty chlorowodorku (R)-8-chloro-1-metylo-2,3,4,5-tetrahydro-1H-3-benzazepiny |
EP1846408B1 (en) | 2005-01-14 | 2013-03-20 | Janssen Pharmaceutica NV | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
ES2345997T3 (es) | 2005-01-14 | 2010-10-07 | Janssen Pharmaceutica Nv | Pirazolopiramidinas como inhibidores de las quinasas del ciclo celular. |
US20060183758A1 (en) | 2005-02-17 | 2006-08-17 | Cb Research And Development, Inc. | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans |
AU2006232294A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods |
US7737279B2 (en) | 2005-05-10 | 2010-06-15 | Bristol-Myers Squibb Company | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same |
US7593820B2 (en) | 2005-05-12 | 2009-09-22 | Cytopia Research Pty Ltd | Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof |
EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
KR20080026654A (ko) | 2005-07-14 | 2008-03-25 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로시클릭 야누스 키나제 3 억제제 |
EP1919924A2 (en) | 2005-08-16 | 2008-05-14 | Irm, Llc | Compounds and compositions as protein kinase inhibitors |
BRPI0617534A2 (pt) * | 2005-09-23 | 2011-07-26 | Memory Pharm Corp | Composto, composição farmacêutica, método para a ativação/estimulação seletiva de receptores nicotínicos de a-7 em um paciente, método para o tratamento de um paciente que sofre de uma doença psicótica, uma doença neurodegenerativa que envolve uma disfunção do sistema colinérgico, e/ou uma condição de degeneração da memória e/ou da cognição, método para o tratamento de um paciente que sofre de demência e/ou uma outra condição com perda da memória, método para o tratamento de um paciente que sofre de degeneração da memória devida à degeneração cognitiva suave devida ao envelhecimento, mal de alzheimer, esquizofrenia, mal de parkinson, mal de huntington, mal de pick, mal de creutzfeldt-jakob, depressão, envelhecimento, trauma na cabeça, acidente vascular cerebral, hipoxia do cns, senilidade cerebral, demência de multiinfarto, hiv e/ou doença cardiovascular, método para o tratamento e/ou a prevenção da demência em um paciente com mal de alzheimer, método para o tratamento de um paciente para a retirada do álcool ou para o tratamento de um paciente com terapia anti-intoxicação, método para o tratamento de um paciente para conferir neuroproteção contra os danos associados com acidentes vasculares cerebrais e isquemia e excitotoxicidade induzida por glutamato, método para o tratamento de um paciente que sofre de vício de nicotina, dor, tontura de fuso horário, obesidade e/ou diabetes, método de indução de um paciente a parar de fumar, método para o tratamento de um paciente que sofre de degeneração cognitiva suave (mci), demência vascular (vad), declínio cognitivo associado com a idade (aacd), amnésia associada com a cirurgia de coração aberto, apreensão cardíaca, anestesia geral, déficits da memória devido à exposição a agentes anestésicos(...) |
US8106066B2 (en) * | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
EP1937683A4 (en) | 2005-09-23 | 2010-08-25 | Coley Pharm Group Inc | PROCESS FOR 1H-IMIDAZO [4,5-C] PYRIDINES AND ANALOGUE THEREOF |
WO2007061764A2 (en) | 2005-11-22 | 2007-05-31 | Merck & Co., Inc. | Tricyclic compounds useful as inhibitors of kinases |
TW201307354A (zh) | 2005-12-29 | 2013-02-16 | Abbott Lab | 蛋白質激酶抑制劑 |
JP5038392B2 (ja) | 2006-04-03 | 2012-10-03 | エフ.ホフマン−ラ ロシュ アーゲー | 鏡像異性的に富化した環式β−アリール又はヘテロアリールカルボン酸の調製方法 |
US8008332B2 (en) | 2006-05-31 | 2011-08-30 | Takeda San Diego, Inc. | Substituted indazoles as glucokinase activators |
JP5793828B2 (ja) | 2006-08-14 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | フリバンセリンの製剤及びその製造方法 |
US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
CA2665214A1 (en) | 2006-10-06 | 2008-05-29 | Abbott Laboratories | Novel imidazothiazoles and imidazoxazoles |
CN101578285A (zh) | 2007-01-12 | 2009-11-11 | 安斯泰来制药株式会社 | 稠合吡啶化合物 |
CN101230059B (zh) * | 2007-01-23 | 2011-08-17 | 上海恒瑞医药有限公司 | 双环氮杂烷类衍生物、其制备方法及其在医药上的用途 |
CA2676665A1 (en) | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | Modulators of mitotic kinases |
WO2008112695A2 (en) | 2007-03-12 | 2008-09-18 | Irm Llc | Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment |
US7691869B2 (en) | 2007-03-30 | 2010-04-06 | King Pharmaceuticals Research And Development, Inc. | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity |
CN101663027B (zh) | 2007-05-07 | 2013-02-27 | 赢创罗姆有限责任公司 | 包含肠溶包衣的可促进药物释放的固体剂型 |
MX2009011830A (es) | 2007-05-11 | 2009-11-13 | Pfizer | Compuestos amino-heterociclicos. |
EP2170337A4 (en) | 2007-06-28 | 2013-12-18 | Abbvie Inc | NEW TRIAZOLOPYRIDAZINE |
US20090022789A1 (en) | 2007-07-18 | 2009-01-22 | Supernus Pharmaceuticals, Inc. | Enhanced formulations of lamotrigine |
PL2250172T3 (pl) | 2008-02-25 | 2012-01-31 | Hoffmann La Roche | Pirolopirazynowe inhibitory kinazy |
EP2247592B1 (en) | 2008-02-25 | 2011-08-31 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
JP5485178B2 (ja) | 2008-02-25 | 2014-05-07 | エフ.ホフマン−ラ ロシュ アーゲー | ピロロピラジンキナーゼ阻害剤 |
WO2009108827A1 (en) | 2008-02-29 | 2009-09-03 | Wyeth | Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof |
EP2271317B1 (de) | 2008-03-28 | 2017-04-19 | Boehringer Ingelheim International GmbH | Verfahren zur herstellung von säurepellets |
CN102118968A (zh) | 2008-06-10 | 2011-07-06 | 雅培制药有限公司 | 新的三环化合物 |
AU2009266806A1 (en) | 2008-07-03 | 2010-01-07 | Exelixis Inc. | CDK modulators |
CN101638423B (zh) * | 2008-07-29 | 2012-09-05 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 根皮苷衍生物及其制备方法和用途 |
KR101275980B1 (ko) | 2009-02-24 | 2013-06-17 | 머크 캐나다 인크. | Crth2 수용체 길항제로서의 인돌 유도체 |
WO2010117796A2 (en) | 2009-03-30 | 2010-10-14 | Codexis, Inc. | Processes for the preparation of alpha-chloroketones from carboxylic acids |
KR20110137364A (ko) | 2009-04-14 | 2011-12-22 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 피롤로피리딘 유도체 |
CN101904814A (zh) | 2009-06-04 | 2010-12-08 | 上海恒瑞医药有限公司 | 制备载药乳剂的方法 |
FR2947276B1 (fr) | 2009-06-24 | 2012-10-26 | Seppic Sa | Composition cosmetique a base de resines echangeuses d'ions chargees avec des lipoaminoacides |
US8361962B2 (en) | 2009-07-27 | 2013-01-29 | Roche Palo Alto Llc | Tricyclic inhibitors of JAK |
US9078830B2 (en) | 2009-07-31 | 2015-07-14 | Ranbaxy Laboratories Limited | Multi-layered, multiple unit pharmaceutical compositions |
RU2012127368A (ru) | 2009-12-01 | 2014-01-10 | Эбботт Лэборетриз | Новые трициклические соединения |
WO2011068881A1 (en) | 2009-12-01 | 2011-06-09 | Abbott Laboratories | Novel tricyclic compounds |
CA2788526A1 (en) | 2010-05-14 | 2011-11-17 | Alembic Limited | Extended release formulations of desvenlafaxine base |
AR081848A1 (es) | 2010-06-09 | 2012-10-24 | Presidio Pharmaceuticals Inc | Inhibidores de la proteina ns5a del vhc |
WO2011156698A2 (en) | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
EP2621914B1 (en) | 2010-09-27 | 2016-12-28 | Abbott GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
US9011912B2 (en) | 2010-10-07 | 2015-04-21 | Abon Pharmaceuticals, Llc | Extended-release oral dosage forms for poorly soluble amine drugs |
US20120330012A1 (en) | 2011-04-29 | 2012-12-27 | Abbott Laboratories | Novel Tricyclic Compounds |
US20130072470A1 (en) | 2011-09-21 | 2013-03-21 | Abbvie Inc. | Novel tricyclic compounds |
FR2991171B1 (fr) | 2012-06-01 | 2014-05-23 | Galderma Res & Dev | Procede de preparation d'une composition dermatologique comprenant des oleosomes |
WO2014004863A2 (en) | 2012-06-27 | 2014-01-03 | Alzheimer's Institute Of America, Inc. | Compounds, compositions, and therapeutic uses thereof |
MX2015011509A (es) | 2013-03-15 | 2016-05-31 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina. |
JP6041823B2 (ja) | 2013-03-16 | 2016-12-14 | ファイザー・インク | トファシチニブの経口持続放出剤形 |
EP3060234A1 (en) | 2013-10-24 | 2016-08-31 | AbbVie Inc. | Jak1 selective inhibitor and uses thereof |
AU2015308878A1 (en) | 2014-08-27 | 2017-03-02 | Abbvie Inc. | Topical formulation |
CA2987867C (en) | 2015-06-09 | 2023-06-27 | Capsugel Belgium Nv | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
JP2018527337A (ja) | 2015-08-13 | 2018-09-20 | ファイザー・インク | 二環式縮合ヘテロアリールまたはアリール化合物 |
MX2018002402A (es) | 2015-08-27 | 2018-04-11 | Pfizer | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
CN116270645A (zh) | 2015-10-16 | 2023-06-23 | 艾伯维公司 | 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
PL3383363T3 (pl) | 2015-11-30 | 2021-05-31 | Anacor Pharmaceuticals, Inc. | Preparaty farmaceutyczne do stosowania miejscowego do leczenia stanów związanych z zapaleniem |
WO2017126488A1 (ja) | 2016-01-18 | 2017-07-27 | 持田製薬株式会社 | 乾癬治療用組成物および治療方法 |
JP7096592B2 (ja) | 2016-02-16 | 2022-07-06 | ワシントン・ユニバーシティ | Jak阻害剤およびこれらの利用 |
EP3481381A4 (en) | 2016-07-06 | 2020-01-01 | Durect Corporation | ORAL PHARMACEUTICAL FORM WITH ACTIVE COMPOSITION, BARRIER AND ACTIVE LAYER |
JP2020510016A (ja) | 2017-03-09 | 2020-04-02 | アッヴィ・インコーポレイテッド | クローン病及び潰瘍性大腸炎を処置する方法 |
US11564922B2 (en) | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
-
2016
- 2016-10-17 CN CN202211671776.7A patent/CN116270645A/zh active Pending
- 2016-10-17 SG SG11201802990RA patent/SG11201802990RA/en unknown
- 2016-10-17 CN CN201680070259.0A patent/CN108368121B/zh active Active
- 2016-10-17 EP EP23151673.3A patent/EP4219503A1/en active Pending
- 2016-10-17 MX MX2018004605A patent/MX2018004605A/es unknown
- 2016-10-17 BR BR112018007677-5A patent/BR112018007677A2/pt active IP Right Grant
- 2016-10-17 SG SG10201913986YA patent/SG10201913986YA/en unknown
- 2016-10-17 CN CN202211671688.7A patent/CN116284011A/zh active Pending
- 2016-10-17 SG SG10201913989QA patent/SG10201913989QA/en unknown
- 2016-10-17 KR KR1020187013644A patent/KR20180081523A/ko not_active Application Discontinuation
- 2016-10-17 SG SG10201913997WA patent/SG10201913997WA/en unknown
- 2016-10-17 SG SG10201913999PA patent/SG10201913999PA/en unknown
- 2016-10-17 CN CN202211671778.6A patent/CN116270646A/zh active Pending
- 2016-10-17 SG SG10201913987UA patent/SG10201913987UA/en unknown
- 2016-10-17 SG SG10201913990RA patent/SG10201913990RA/en unknown
- 2016-10-17 BR BR122022024925-6A patent/BR122022024925B1/pt active IP Right Grant
- 2016-10-17 EP EP16788358.6A patent/EP3362455A1/en not_active Withdrawn
- 2016-10-17 CA CA3002220A patent/CA3002220C/en active Active
- 2016-10-17 WO PCT/US2016/057372 patent/WO2017066775A1/en active Application Filing
- 2016-10-17 CA CA3123260A patent/CA3123260A1/en active Pending
- 2016-10-17 US US15/295,561 patent/US20170129902A1/en not_active Abandoned
- 2016-10-17 AU AU2016340167A patent/AU2016340167B2/en active Active
- 2016-10-17 SG SG10201913993QA patent/SG10201913993QA/en unknown
- 2016-10-17 RU RU2018117889A patent/RU2018117889A/ru unknown
- 2016-10-17 JP JP2018517576A patent/JP6770775B2/ja active Active
-
2017
- 2017-08-21 US US15/682,457 patent/US9879019B2/en active Active
- 2017-08-21 US US15/682,451 patent/US9879018B2/en active Active
- 2017-11-03 US US15/803,538 patent/US9951080B2/en active Active
- 2017-12-29 US US15/857,892 patent/US9963459B1/en active Active
-
2018
- 2018-02-07 US US15/891,306 patent/US10017517B2/en active Active
- 2018-02-07 US US15/891,012 patent/US20190023714A1/en not_active Abandoned
- 2018-02-28 US US15/908,347 patent/US10344036B2/en active Active
- 2018-04-04 US US15/945,225 patent/US10202393B2/en active Active
- 2018-04-04 US US15/945,231 patent/US10202394B2/en active Active
- 2018-04-11 IL IL258654A patent/IL258654A/en unknown
- 2018-04-13 MX MX2021013812A patent/MX2021013812A/es unknown
-
2019
- 2019-01-29 HK HK19101482.2A patent/HK1263380A1/zh unknown
- 2019-06-26 US US16/453,684 patent/US10519164B2/en active Active
- 2019-07-01 US US16/458,622 patent/US10597400B2/en active Active
- 2019-10-17 US US16/656,237 patent/US20200291040A1/en not_active Abandoned
-
2020
- 2020-02-11 US US16/787,251 patent/US10730883B2/en active Active
- 2020-06-18 US US16/905,667 patent/US10981923B2/en active Active
- 2020-08-03 US US16/983,701 patent/US10981924B2/en active Active
- 2020-09-24 JP JP2020159855A patent/JP7358317B2/ja active Active
-
2021
- 2021-02-24 US US17/184,194 patent/US20210363149A1/en not_active Abandoned
- 2021-04-14 US US17/230,288 patent/US11186584B2/en active Active
- 2021-04-14 US US17/230,418 patent/US11198697B1/en active Active
- 2021-05-28 IL IL283531A patent/IL283531A/en unknown
- 2021-09-24 AU AU2021236570A patent/AU2021236570B2/en active Active
-
2022
- 2022-05-13 JP JP2022079226A patent/JP2022107001A/ja active Pending
- 2022-05-27 US US17/827,054 patent/US11535624B2/en active Active
- 2022-09-23 US US17/951,332 patent/US11680069B2/en active Active
- 2022-09-23 US US17/951,334 patent/US11661425B2/en active Active
-
2023
- 2023-01-06 US US18/094,266 patent/US11718627B2/en active Active
- 2023-01-06 US US18/094,263 patent/US11773105B2/en active Active
- 2023-02-27 US US18/174,736 patent/US11787815B1/en active Active
- 2023-02-27 US US18/174,738 patent/US11780847B1/en active Active
- 2023-03-01 US US18/176,647 patent/US11795175B2/en active Active
- 2023-06-02 US US18/328,325 patent/US20240034740A1/en active Pending
- 2023-06-02 US US18/328,350 patent/US20230312595A1/en active Pending
- 2023-06-06 US US18/329,980 patent/US20230331735A1/en active Pending
- 2023-06-06 US US18/329,988 patent/US20230322794A1/en active Pending
- 2023-06-06 US US18/329,986 patent/US20230348481A1/en active Pending
- 2023-06-12 JP JP2023096042A patent/JP2023113917A/ja active Pending
- 2023-07-28 US US18/361,582 patent/US20230374027A1/en not_active Abandoned
- 2023-09-18 US US18/369,272 patent/US20240010656A1/en active Pending
- 2023-10-19 AU AU2023251492A patent/AU2023251492A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283531A (en) | Processes for the preparation of (3s,4r)-3-ethyl-4-(3h- imidiazo[1,2-a]pyrrolo[2, 3-e]-pyrazin-8-yl)-n-(2,2,2- Trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | |
IL268737A (en) | Processes for the preparation of benzodiapine derivatives | |
IL266170A (en) | A process for the preparation of pyrazolo[1,5-a]pyrimidines and their salts | |
EP3468973A4 (en) | SOLID FORMS OF VENETOCLAX AND METHOD FOR PRODUCING VENETOCLAX | |
EP3710009A4 (en) | METHOD FOR THE RESOLUTION OF BENZODIAZEPIN-2-ONE AND BENZOAZEPIN-2-ONE DERIVATIVES | |
IL250280B (en) | Spiro[3h-indole-3, 2'-pyrrolidine]-2(1h)-one compounds, and their derivatives and pharmaceutical preparations containing them | |
IL270909A (en) | Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor | |
EP3258962A4 (en) | Mixed allergen compositions and methods for using the same | |
EP3546460A4 (en) | PYRIMIDO [5,4-B] INDOLIZIN OR PYRIMIDO [5,4-B] PYRROLIZIN COMPOUND, PRODUCTION METHOD AND USE THEREOF | |
IL262257B (en) | 1, 5, -dihydro-4h -pyrazolo[3, 4-d]pyrimidin-4-one and 1, 5, -dihydro-4h -pyrazolo[3, 4-c]pyridin-4-one as pde1 inhibitors | |
EP3440719A4 (en) | CONNECTING CLOSURE METHOD FOR INTEGRATING MRAM DEVICES AND RESULTING STRUCTURES | |
HK1247203A1 (zh) | 取代的咪唑並[1,2-α]吡啶-2-基胺化合物及其藥物組合物和使用方法 | |
HK1256044A1 (zh) | 吡啶並[1,2-a]嘧啶酮類似物、其晶型、其中間體及其製備方法 | |
EP3120994A4 (en) | Hollow structural body and component for vehicles | |
PL3135110T3 (pl) | Pochodne 1,7-diarylo-1,6-heptadieno-3,5-dionu, sposób ich wytwarzania i ich zastosowanie | |
IL251107B (en) | History of [2h]-imidazo-[1,2-a]pyrazolo[3,4-e]pyrimidine-4(5h)-one, pharmaceutical preparations containing them and their use in disorders of the central nervous system. | |
GB201802644D0 (en) | Monocyclic,thieno, pyrido and pyrrolo pyrimidine compounds and methods of use and manufacture of the same | |
SG11202001266XA (en) | Process for the preparation of low haze and color stable styrenic polymers | |
IL253427A0 (en) | The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose | |
HK1257427A1 (zh) | 用於製備2-吡唑並[1,5-a]吡嗪-2-基吡啶並[1,2-a]嘧啶-4-酮的方法 | |
IL266313A (en) | crystal of a pyrido[4,3-d]pyrimidine derivative or its solvate | |
IL274560A (en) | A process for the preparation of raltagravir | |
EP3302784A4 (en) | Adsorbent bioprocessing clarification agents and methods of making and using the same |